Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicina (Kaunas)
Asıl Yazarlar: Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://ncbi.nlm.nih.gov/pubmed/31640191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller